CD276 and ovarian cancer: It has been demonstrated that B7-H3 expression in ovarian cancer occurs independently of the status of the BRCA mutation,41 suggesting its potential as a broadly applicable therapeutic target for both HRD-positive and HRD-negative ovarian cancer patients.